PMC:7650537 / 21796-22029 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T138","span":{"begin":68,"end":73},"obj":"Body_part"}],"attributes":[{"id":"A138","pred":"fma_id","subj":"T138","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"These sensitivities can be even higher, as retesting of the initial serum from patient 4 in the second part of our study revealed the presence of low-level neutralizing antibodies (1:10 vs. 1:20–1:40; Figure 5 and Figures S1 and S2)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T12","span":{"begin":68,"end":73},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"These sensitivities can be even higher, as retesting of the initial serum from patient 4 in the second part of our study revealed the presence of low-level neutralizing antibodies (1:10 vs. 1:20–1:40; Figure 5 and Figures S1 and S2)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T179","span":{"begin":222,"end":224},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T180","span":{"begin":229,"end":231},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T181","span":{"begin":229,"end":231},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"}],"text":"These sensitivities can be even higher, as retesting of the initial serum from patient 4 in the second part of our study revealed the presence of low-level neutralizing antibodies (1:10 vs. 1:20–1:40; Figure 5 and Figures S1 and S2)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T78","span":{"begin":229,"end":231},"obj":"Chemical"}],"attributes":[{"id":"A78","pred":"chebi_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"}],"text":"These sensitivities can be even higher, as retesting of the initial serum from patient 4 in the second part of our study revealed the presence of low-level neutralizing antibodies (1:10 vs. 1:20–1:40; Figure 5 and Figures S1 and S2)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T172","span":{"begin":0,"end":233},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These sensitivities can be even higher, as retesting of the initial serum from patient 4 in the second part of our study revealed the presence of low-level neutralizing antibodies (1:10 vs. 1:20–1:40; Figure 5 and Figures S1 and S2)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"392","span":{"begin":79,"end":86},"obj":"Species"}],"attributes":[{"id":"A392","pred":"tao:has_database_id","subj":"392","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"These sensitivities can be even higher, as retesting of the initial serum from patient 4 in the second part of our study revealed the presence of low-level neutralizing antibodies (1:10 vs. 1:20–1:40; Figure 5 and Figures S1 and S2)."}